SGF73 Antibody

What is SGF73 and why is it important in research?

SGF73 is a component of the Spt-Ada-Gcn5-acetyltransferase (SAGA) complex in yeast, functioning as a homologue of human ataxin-7 (ATXN7). It plays critical roles in transcriptional regulation through chromatin remodeling and modification. SGF73 is particularly important in research because it serves as a vital component that facilitates the recruitment of SAGA to gene promoters and aids in the formation of the preinitiation complex (PIC) assembly. This makes it essential for proper transcriptional activation of SAGA-dependent genes . Additionally, deletion of SGF73 has been shown to dramatically extend replicative lifespan in yeast, connecting it to aging research . SGF73's role in maintaining SAGA integrity in vivo makes it a key target for understanding transcriptional regulation in eukaryotes.

What structural domains characterize SGF73 protein?

SGF73 contains an SCA7 domain characterized by an atypical zinc-finger motif. The solution structures of the SCA7 domain reveal a distinct fold organized around a zinc-binding site. Specifically:

• The yeast Sgf73 SCA7 domain spans amino acids 211-283

• This domain exhibits nucleosome-binding properties

• The SCA7 domain is not required for recruitment of SGF73 into the SAGA complex

• The zinc-finger motif creates a structural foundation that determines functional properties

The structural properties of the SCA7 domain differ between SGF73/ATXN7 and related proteins like ATXN7L3, providing a molecular basis for their different functions despite sharing a common zinc-finger motif .

How does SGF73 function within the SAGA complex?

SGF73 serves several critical functions within the SAGA complex:

• SAGA Integrity Maintenance: SGF73 is required to maintain the structural integrity of SAGA in vivo. Deletion of SGF73 significantly impairs recruitment of other SAGA components (including Spt20p and TAF10p) to gene promoters .

• Transcriptional Activation: SGF73 facilitates the formation of the preinitiation complex (PIC) at SAGA-dependent promoters, which is essential for proper transcriptional activation. ChIP assays show that SGF73 is recruited to the upstream activating sequence (UAS) of SAGA-dependent genes like GAL1 in an activator-dependent manner .

• HAT-dependent and HAT-independent Regulation: Interestingly, SGF73 can stimulate PIC formation at SAGA-dependent promoters through both histone acetyltransferase (HAT)-dependent and HAT-independent mechanisms, depending on the specific gene context .

• Deubiquitination Activity: As part of SAGA's deubiquitination module, SGF73 plays a role in histone H2B deubiquitination, which affects chromatin structure and function .

What are the optimal methods for chromatin immunoprecipitation (ChIP) assays using SGF73 antibodies?

For effective ChIP assays with SGF73 antibodies, researchers should follow these methodological guidelines:

• Epitope Tagging Strategy: For optimal results, integrate a C-terminal epitope tag (13-Myc or 3-haemagglutinin) to SGF73 at its original chromosomal locus. This approach has been validated to maintain protein functionality while enabling efficient immunoprecipitation .

• Crosslinking Protocol: Use formaldehyde-based in vivo crosslinking (typically 1% formaldehyde for 15-20 minutes at room temperature) to capture protein-DNA interactions effectively .

• Cell Growth Conditions: For studies involving galactose-inducible genes, grow cells in YPR (yeast extract containing peptone plus 2% raffinose) to an OD600 of 0.9, then transfer to YPG (yeast extract-peptone plus 2% galactose) for 90 minutes at 30°C prior to formaldehyde crosslinking .

• Antibody Selection: For tagged SGF73, use either c-myc mouse monoclonal antibody (for Myc-tagged proteins) or anti-HA antibodies (for HA-tagged proteins). Ensure antibody specificity through appropriate controls .

• Primer Design: Design promoter-specific primer pairs that can distinguish binding to different promoter regions (e.g., UAS vs. core promoter). For SGF73 studies, include primers for both target regions and irrelevant DNA sequences as negative controls .

• ChIP-Seq Optimization: For genome-wide analyses, process ChIP'd DNA into libraries and perform single-end sequencing (generating ~17 million 50-bp reads per sample). Align raw sequence reads to the appropriate reference genome (e.g., S. cerevisiae S288C genome) .

• Peak Identification: Use HOMER (Hypergeometric Optimization of Motif EnRichment) v4.2 or similar software to identify significant peaks, defined as collections of sequence reads mapping to genomic locations at significantly higher density than background .

How can I validate the specificity of SGF73 antibodies for experimental use?

Validating SGF73 antibody specificity requires a multi-step approach:

• Genetic Controls:

  • Compare immunoprecipitation results between wild-type and SGF73 deletion (Δsgf73) strains

  • The deletion strain should show absence of signal in Western blots and ChIP assays

• Western Blot Validation:

  • Confirm antibody detection of tagged SGF73 at the expected molecular weight

  • Perform immunoblotting of both input and immunoprecipitated samples to verify recovery efficiency

• Functional Complementation Tests:

  • Ensure that tagged versions used for antibody detection maintain protein functionality

  • Perform standard growth assays to confirm that the epitope tag doesn't interfere with SGF73 function

• Cross-reactivity Assessment:

  • Test antibody against related proteins (e.g., ATXN7L3) to ensure specificity

  • Perform immunoprecipitation followed by mass spectrometry to identify all proteins recognized by the antibody

• Peptide Competition Assay:

  • Pre-incubate the antibody with the peptide used for immunization

  • This should block specific binding and reduce or eliminate the signal in subsequent applications

What protein-protein interaction studies can be performed with SGF73 antibodies?

SGF73 antibodies can be employed in various protein-protein interaction studies:

• Co-Immunoprecipitation (Co-IP):

  • Use SGF73 antibodies to pull down SGF73 and associated proteins from cell lysates

  • Identify interacting proteins through Western blotting or mass spectrometry

  • This approach has successfully demonstrated SGF73's association with SAGA components

• Tandem Affinity Purification (TAP):

  • Utilize strains with TAP-tagged SAGA components (e.g., Spt20-TAP) in combination with SGF73 antibodies

  • This allows for sequential purification steps to identify stable protein complexes

  • Standard TAP procedures can be followed with minor modifications

• GST-Pulldown Assays:

  • Express GST-SCA7 fusion proteins (e.g., SGF73 211-283, ATXN7 330-401)

  • Use these in combination with SGF73 antibodies to validate specific domain interactions

  • This approach has successfully characterized the nucleosome-binding properties of the SCA7 domain

• Chromatin-Associated Protein Complexes:

  • Employ ChIP followed by re-ChIP (sequential ChIP) using SGF73 antibodies and antibodies against other factors

  • This can reveal co-occupancy of SGF73 with other proteins at specific genomic locations

  • The method has demonstrated that SGF73 and other SAGA components co-occupy the GAL1 UAS

How does SGF73 contribute to transcriptional regulation?

SGF73 contributes to transcriptional regulation through multiple mechanisms:

• SAGA Complex Recruitment: SGF73 is required for proper recruitment of the SAGA complex to gene promoters. ChIP assays demonstrate that deletion of SGF73 significantly reduces recruitment of SAGA components like Spt20p and TAF10p to the GAL1 UAS .

• Preinitiation Complex (PIC) Formation: SGF73 facilitates the assembly of the PIC at SAGA-dependent promoters. Experiments show that deletion of SGF73 dramatically reduces recruitment of TATA-binding protein (TBP) and RNA polymerase II (Rpb1p) to the GAL1 core promoter .

• Gene-Specific Regulation Mechanisms:

  • For some genes (e.g., GAL1, ADH1), SGF73 facilitates PIC formation independent of histone H3 acetylation or HAT activity

  • For other genes (e.g., PHO84), SGF73 stimulates PIC formation in a HAT-dependent manner

  • This suggests SGF73 employs context-dependent mechanisms for transcriptional regulation

• Ribosomal Protein Gene Regulation: ChIP-Seq analysis has identified 388 unique genomic regions bound by SGF73, with notable enrichment at promoters of ribosomal protein (RP) genes. Approximately half of SGF73-occupied RP genes show significantly reduced expression in sgf73Δ mutants .

What is the relationship between SGF73 and replicative lifespan extension?

The relationship between SGF73 and replicative lifespan (RLS) extension is characterized by:

• Dramatic RLS Extension Effect: Deletion of SGF73 significantly extends replicative lifespan in yeast, making it an important target for aging research .

• Ribosomal Protein Gene Regulation: ChIP-Seq analysis revealed that of 388 Sgf73 binding sites, 33 correspond to 5′ regions of genes implicated in RLS extension, including 20 genes encoding ribosomal proteins (RPs) .

• Genetic Interaction Data: Double null strains lacking both SGF73 and a Sgf73-regulated, RLS-linked RP gene exhibit no further increase in replicative lifespan compared to sgf73Δ alone. This suggests that altered ribosomal protein expression is a key mechanism underlying SGF73-mediated RLS extension .

• TOR Pathway Connection: sgf73Δ mutants display altered acetylation of Ifh1, an important regulator of RP gene transcription that is connected to the Target of Rapamycin (TOR) pathway. This suggests SGF73 may influence lifespan through interactions with nutrient-sensing pathways .

• Expression Changes: Half of Sgf73-occupied, RLS-linked RP genes show significantly reduced expression in sgf73Δ mutants, potentially connecting altered translational capacity to lifespan extension .

How can SGF73 antibodies be used to study chromatin dynamics?

SGF73 antibodies offer valuable tools for studying various aspects of chromatin dynamics:

• Nucleosome Occupancy Analysis:

  • SGF73 antibodies can be used in ChIP assays to examine histone eviction during transcriptional activation

  • Studies show that when PIC is not formed in Δsgf73 mutants, histone H3 is not evicted from promoters like GAL1

  • This allows researchers to connect SGF73 function to nucleosome dynamics

• Histone Modification Studies:

  • Combined use of SGF73 antibodies with histone modification-specific antibodies (e.g., H3K9ac, H3K4me3)

  • This approach can reveal connections between SGF73 recruitment and specific histone modifications

  • SGF73's role in both HAT-dependent and HAT-independent regulation makes this particularly informative

• Histone Deubiquitination Monitoring:

  • SGF73 antibodies can be used to study SAGA's deubiquitination module

  • Analysis of H2Bub1/H2B ratios in conjunction with SGF73 occupancy provides insights into the relationship between SGF73 binding and histone H2B deubiquitination

• SCA7 Domain Function:

  • Antibodies targeting specific domains (like the SCA7 domain) can help dissect their roles in chromatin binding

  • The SCA7 domain of SGF73 binds to nucleosomes, and antibodies can be used to study this interaction

How do mutations in SGF73 affect its function in SAGA complex assembly and activity?

The impact of SGF73 mutations on SAGA complex assembly and activity can be assessed through:

• Domain-Specific Mutational Analysis:

  • Site-directed mutagenesis can be used to generate specific mutations in SGF73 domains

  • The QuikChange Lightning Site-Directed Mutagenesis Kit has been successfully employed for this purpose

  • Key residues in the SCA7 domain zinc-finger motif are particularly important targets

• SAGA Complex Integrity Assessment:

  • Mutations in SGF73 can disrupt SAGA complex integrity

  • ChIP assays comparing wild-type and mutant SGF73 can reveal differences in recruitment of other SAGA components to target promoters

  • This approach has demonstrated that SGF73 is required for recruitment of components like Spt20p and TAF10p

• Functional Complementation Studies:

  • Plasmid-based expression of mutant SGF73 variants in sgf73Δ strains

  • Analysis of whether mutants can rescue phenotypes associated with SGF73 deletion

  • Key readouts include transcription of SAGA-dependent genes, PIC formation, and SAGA recruitment

• Biochemical Activity Assays:

  • Analysis of histone modification changes (especially H3 acetylation and H2B deubiquitination)

  • Mutations affecting SGF73 can alter SAGA's enzymatic activities

  • Quantification of the H2Bub1/H2B ratio using ImageJ software can reveal functional consequences of mutations

What techniques can be used to study the genome-wide occupancy of SGF73?

To study genome-wide occupancy of SGF73, researchers can employ:

• ChIP-Seq Methodology:

  • Use C-terminal epitope-tagged SGF73 (13-Myc tag recommended)

  • Perform chromatin immunoprecipitation followed by next-generation sequencing

  • Generate approximately 17 million 50-bp reads per sample for adequate coverage

  • Align raw sequence reads to the appropriate reference genome (e.g., S. cerevisiae S288C genome sacCer3)

• Peak Calling and Analysis:

  • Use HOMER (Hypergeometric Optimization of Motif EnRichment) or similar tools

  • Define significant peaks as regions with read density significantly higher than background

  • Rank peaks by tag counts (number of unique reads mapping to each region)

  • This approach has successfully identified 388 unique SGF73 occupancy sites

• Integration with Transcriptome Data:

  • Combine ChIP-Seq results with RNA-Seq or microarray data from wild-type and sgf73Δ strains

  • This integration can reveal functional consequences of SGF73 binding

  • The approach has shown that approximately half of SGF73-occupied ribosomal protein genes show altered expression in sgf73Δ mutants

• Comparative Genomic Analyses:

  • Compare SGF73 binding sites with datasets of other transcription factors or chromatin modifiers

  • Overlap analysis with gene sets implicated in specific biological processes (e.g., RLS extension)

  • This strategy has identified 33 genes that both bind SGF73 and promote RLS when deleted

How can I differentiate between direct and indirect effects of SGF73 on gene expression?

Differentiating between direct and indirect effects of SGF73 on gene expression requires:

• Integrated Genomic Approaches:

  • Combine SGF73 ChIP-Seq data with RNA-Seq or microarray data

  • Genes that both bind SGF73 and show expression changes in sgf73Δ mutants are likely direct targets

  • This approach has identified direct SGF73 targets among ribosomal protein genes

• Time-Course Studies:

  • Analyze transcriptional responses at multiple time points after SGF73 inactivation

  • Early response genes are more likely to be direct targets

  • Compare with kinetics of changes in SAGA recruitment and PIC formation at selected promoters

• Targeted Mutational Analysis:

  • Generate SGF73 mutants affecting specific functions (e.g., SAGA recruitment vs. nucleosome binding)

  • Characterize differential effects on distinct gene sets

  • This can help dissect the direct mechanisms by which SGF73 regulates specific genes

• Genetic Interaction Studies:

  • Create double mutants lacking SGF73 and other transcriptional regulators

  • Analyze epistatic relationships to place SGF73 in regulatory hierarchies

  • Double null strains of sgf73Δ with deletions of SGF73-regulated genes have helped establish direct functional relationships

What are common challenges in SGF73 immunoprecipitation and how can they be addressed?

Common challenges in SGF73 immunoprecipitation and their solutions include:

How can I optimize Western blot protocols for detecting SGF73?

To optimize Western blot protocols for SGF73 detection:

• Sample Preparation:

  • For yeast cultures, use a standardized alkaline lysis method: resuspend cells in 100 μl of 200 mM NaOH for 5 minutes at room temperature, then boil pellets in Laemmli buffer for 5 minutes at 100°C

  • Include protease inhibitors to prevent degradation during extraction

• Gel Electrophoresis Parameters:

  • Use 8-10% SDS-PAGE gels for optimal separation of SGF73 (approximately 73 kDa)

  • For tagged versions, adjust percentage based on the added tag size

• Transfer Conditions:

  • Optimize transfer time and voltage for high molecular weight proteins

  • Consider using PVDF membranes instead of nitrocellulose for better protein retention

• Blocking and Antibody Incubation:

  • Block membranes in 5% non-fat dry milk or BSA in TBST

  • For tagged SGF73, use antibodies against the tag (anti-Myc M2 or anti-HA) at optimized dilutions

  • Incubate primary antibodies overnight at 4°C for maximum sensitivity

• Signal Development:

  • Use enhanced chemiluminescence (ECL) detection systems

  • Consider fluorescent secondary antibodies for quantitative analysis

  • ImageJ software can be used for quantification of band intensities

How can I address inconsistent results in ChIP-qPCR experiments with SGF73 antibodies?

To address inconsistent results in ChIP-qPCR experiments:

• Standardize Cell Growth and Induction:

  • For galactose-inducible genes, grow cells in YPR to an OD600 of 0.9, then transfer to YPG for exactly 90 minutes at 30°C

  • For other experiments, ensure consistent OD600 (typically 1.0) across all samples

• Optimize Crosslinking Conditions:

  • Test different formaldehyde concentrations (0.8-1.2%) and crosslinking times (10-20 minutes)

  • Quench with glycine (125 mM final concentration) for consistent time periods

• Sonication Optimization:

  • Standardize sonication conditions to generate consistent chromatin fragment sizes (200-500 bp)

  • Verify fragment size by agarose gel electrophoresis before immunoprecipitation

• Control for Technical Variation:

  • Include internal control regions (e.g., GAL4 ORF as negative control, constitutively active genes as positive controls)

  • Normalize to input DNA for each primer set

• Primer Design and Validation:

  • Design primers for distinct regions (UAS vs. core promoter) with similar amplification efficiencies

  • Validate primers using standard curves with genomic DNA

• Multiple Biological and Technical Replicates:

  • Perform at least three biological replicates

  • Include technical duplicates or triplicates for qPCR

• Sequential ChIP Approach:

  • For challenging targets, consider sequential ChIP with antibodies against known interacting partners (e.g., other SAGA components)

  • This can increase specificity and reduce background